Market Access

Heparin is a critical drug that is highly dependent on the global supply chain and is derived from a highly complex process.

Demand for semaglutide and other GLP-1s is expected to grow exponentially over the next 3–5 years.

As the FDA’s ban on mass compounding of semaglutide takes effect, Novo Nordisk introduces discounted pricing and new patient resources to ensure safe access to Wegovy.

The window of opportunity for launch is short and unforgiving, and the success depends on flawless execution of launch activity across countries and functions.

Identifying the priorities that translate to strong business outcomes—and separating the top performers from the average brands.

Navigating technology and regulatory shifts in pharma revenue management.

Country is poised to offer growth-channel opportunities for global pharma companies ready to scale access, innovation, and profitability.

The argument for weighing clinical points more heavily in the access equation.

Doug Long, VP, industry relations, IQVIA, discusses how soaring demand for GLP-1 therapies is driving reimbursement challenges, shifting distribution models, and expanding the drugs’ potential into new therapeutic areas.

Fran Gregory, VP, emerging therapies, Cardinal Health, emphasizes the need for long-term outcomes tracking and robust health economic modeling to demonstrate the sustained value of advanced therapies and support future payment strategies.

A seminar shares key observations and learnings from the first round of direct price negotiations.

Market access is about aligning internal strategies with external realities that often change without warning and at a frequency likely not experienced by other biopharma executive roles.

Arda Ural discusses the possible impact on how companies plan for growth based on the impact of the tariffs.

CMS’ draft guidance on real-world data study protocols marks a significant move toward transparency and rigor in Medicare coverage decisions.

Lynlee Brown discusses the decisions that companies must make to adjust to the tariffs while also ensuring the ongoing innovation continues.

Four tips for midsized companies when entering new global markets.

How to maximize market-entry performance for new pharma products in an increasingly competitive launch environment.

“We’re going to tariff our pharmaceuticals, and once we do that, they are going to come rushing back into our country," President Donald J. Trump said during a Tuesday night dinner in Washington.

The high-stakes nature of cancer care, coupled with rapid scientific advancements and increasing payer and regulatory pressures, demands a specialized approach beyond traditional market access strategies.

Kimberley Chiang, vice president of biopharma commercial solutions at CoverMyMeds, discusses how the industry leverages data and technology to identify and address affordability issues before they become a barrier to patient access.

A look at the current landscape and how young companies can set the stage for product launch.

HEOR scientists in the pharma industry must balance methodologic rigor with commercial expectations and timelines.

The recent shift in Health Economics and Outcomes Research functions across major pharmaceutical companies highlights a lack of understanding of its value.

In this Pharmaceutical Executive Video Interview, Peter Ax, Founder & CEO of UpScriptHealth, explores ways that digital health platforms can assist pharma companies seeking to maintain accessibility and manage cost pressures.

In this Pharmaceutical Executive Video Interview, Peter Ax, Founder & CEO of UpScriptHealth, explores how tariffs could affect the availability and accessibility of specific medications, particularly for patients relying on direct-to-patient telehealth.